Among eligible candidates with HF with reduced ejection fraction, prescription rates of beta‐blockers and aldosterone receptor antagonists were 59.1% and 87.8% during hospitalization and 46.2% and 64.2% at discharge, respectively. This evidence concerns the gene NR3C2 and hydrops fetalis.